Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q 2025 and will include data from participants who have received capsules from a more recently ma ...

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus ...

Q1 2025 Earnings Call Transcript January 29, 2025 Dolby Laboratories, Inc. beats earnings expectations. Reported EPS is $1.14, expectations were $1.07. Operator: Ladies and gentlemen, thank you for ...

In a report released yesterday, Steve Frankel from Rosenblatt Securities reiterated a Buy rating on Dolby Laboratories (DLB – Research Report), ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Dolby Laboratories (DLB) delivered earnings and revenue surprises of 6.54% and 3.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

DLB's fiscal first-quarter 2025 performance gains from steady growth in the Licensing, and the Products and services segments.

Barrington analyst Patrick Sholl maintained a Buy rating on Dolby Laboratories (DLB – Research Report) today and set a price target of $100.00.

Dolby Laboratories (NYSE:DLB) reported its financial results for the first quarter of 2025, surpassing earnings expectations ...

Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up ...

Dolby Laboratories (NYSE:DLB – Get Free Report) will likely be posting its quarterly earnings results after the market closes ...

Here's a brief overview of the earnings report. Dolby Laboratories beat estimated earnings by 16.0%, reporting an EPS of $1.14 versus an estimate of $0.98. Revenue was up $41.42 million from the same ...